## Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI)/Case Report Form Cover Sheet

As the COVID-19 situation in the State of Michigan rapidly evolves, MDHHS continues to adapt resource and capacity planning to support the varied needs of our partners in healthcare and local public health organizations. The Michigan COVID-19 Laboratory Emergency Response Network (MiCLERN) is used to coordinate scarce resources and increase laboratory capacity. The MiCLERN provider hotline (888-277-9894) was stood up to enable providers to gain access to testing resources. MDHHS recently ordered that all health professionals should conduct testing for the Novel Coronavirus in accordance with the COVID-19 prioritization criteria published by MDHHS.

#### A.) Change in Prioritization Criteria

Given the shortage of specimen collection and laboratory testing resources for COVID-19 in the nation and revised guidance from the U.S. Public Health Service, MDHHS is revising the prioritization criteria for the collection and testing of specimens for COVID-19 testing. At this time, Priority Groups One and Two in the PHS Guidance (https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html) are eligible for testing by health care providers in Michigan:

- 1.) Ensuring optimal care options for all hospitalized patients, lessen the risk of healthcare-associated infections, and maintain the integrity of the U.S. healthcare system. This includes:
  - Hospitalized Patients
  - · Healthcare facility workers with symptoms
- 2.) Ensuring that those at highest risk of complication of infection are rapidly identified and appropriately triaged. This includes:
  - Patients in long-term care facilities with symptoms
  - Patients over age 65 years with symptoms
  - Patients with underlying conditions with symptoms
  - First responders with symptoms

While not required, MDHHS does recommend that health care providers first attempt to rule out other potential etiologies through available testing means (e.g., rapid influenza tests or respiratory infectious disease panel [RIDP]) for these patients before testing for COVID-19. MiCLERN agents will document these efforts in the PUI issuance process. We believe that this model will help to preserve strained testing and resource capacity in the system and will meet the needs of both high disease-burdened areas and non-high-burdened areas of the State alike.

#### B.) Expansion of access to PUI authorization

To reduce the time burden on busy health care providers, MDHHS, in consultation with the Michigan Health and Hospital Association, is broadening access to PUI authorization for testing of inpatient specimens or symptomatic health care worker specimens. Hospitals may have their physicians consult with a member of their health system (most commonly Infection Prevention) to input the patient into the Michigan Disease Surveillance System (MDSS) to receive a PUI Number (the MDSS Investigation ID). The hospital, for inpatient specimens, may enter data into MDSS in place of calling the MiCLERN 24/7 hotline. If sending to the MDHHS BOL, the submitter must continue to put the PUI number on the MDHHS BOL laboratory requisition form for the sample to be tested.

If this process is not feasible for hospitals, they may continue to call MiCLERN at (888) 277-9894 for approval for testing.

At this time, MDHHS is asking that providers and/or Infection Prevention personnel continue to fax the Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI) Case Report Form and Cover Sheet the local health department of patient residence. However, MDHHS is revising PUI Case Report Guidance in the coming days to reduce the data collection burden.

Version date: 03/29/2020

## Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI)/Case Report Form Cover Sheet

#### C.) Reminder about MDHHS Bureau of Laboratories (BOL) submissions

When submitting specimens to BOL for testing, submitters must include the PUI on all necessary BOL test requisitions documents and on the specimen container. BOL prioritizes specimen testing relative to those that present the greatest public health concern. BOL will not prioritize specimens that arrive without a corresponding PUI identifier.

Upon completion of the test, BOL will notify both the ordering physician and the patient's respective local health department of the results. Healthcare providers should not contact the MDHHS public information hotline or the MiCLERN Provider hotline for test results. Agents responding to calls on both hotlines do not have access to the test results. Healthcare providers should not refer patients to these hotlines or any state agencies to obtain their test results as MDHHS will not provide results directly to patients. These calls delay work being done to process specimens and frustrates patients.

MDHHS is making these changes to ensure that testing is available for decision making to protect the health care work force and those most vulnerable to severe outcomes of COVID-19. Thank you for all you do to serve the residents of Michigan at this difficult time.

For the latest information on Michigan's response to COVID-19, please visit <a href="www.michigan.gov/coronavirus">www.michigan.gov/coronavirus</a>. You may also email our Community Health Emergency Coordination Center at: checcdeptcoor@michigan.gov.19

Version date: 03/29/2020

## Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI)/Case Report Form Cover Sheet

### **Patient Information:**

First name: Last name:					
Date of birth:/	Age:	Sex: Female	Male		
Patient residence street address:		City:			
County:	State:	Zip	Code:		
Patient phone number(s):					
Patient hospital ID (Medical Record) nu	ımber:				
Submitting Facility Information:					
Reporting healthcare facility:					
Reporting healthcare facility cor	ntact name and title:				
Healthcare facility contact	t phone number:				
Reason for testing:					
<ol> <li>Ensures optimal care options for all and maintain the integrity of the U.S Hospitalized patients</li> </ol>	•	s, lessen the risk of he	ealthcare-associated infections,		
Healthcare facility workers w	vith symptoms				
2.) Ensures those at highest risk of comp	plication of infection	are rapidly identified	I and appropriately triaged		
_		•	egate living arrangement (i.e., skilled nursing facilities, etc.)		
Patients over age 65 years w	ith symptoms				
Patients with underlying con	ditions with symptor	ns			
First responders with sympto	oms				
Specimen Being Submitted to:  MDHHS BOL- PUI (nCoV) ID#: MI-  Assigned by case entry into MDSS by	healthcare facility st	(Required) aff or via the MiCLERN	•		
Clinical or Commercial lab. PUI (nCo	V) ID is not required				

Version date: 03/29/2020

CDC 2	019-nCoV ID:	Form Ap	proved: OMB: 0920-1011 Exp. 4/23/2020
PATIEN	T IDENTIFIER INFORMA	ATION IS NOT TRANSMITTED TO CDC	
Patient first name	Patient last name	Date of birth (MM	M/DD/YYYY):/
PATIEN	T IDENTIFIER INFORM	ATION IS NOT TRANSMITTED TO CDC	
Human	Infection wi	ith 2019 Novel Coron	avirus
Person Under	Investigation	on (PUI) and Case Re	port Form
Reporting jurisdiction:	•	state/local ID:	
Reporting health department:		2019-nCoV ID:	
Contact ID <sup>a</sup> :  a. Only complete if case-patient is a known contact of prior source case-pa		SS loc. rec. ID/Case ID b:  DC 2019-nCoV ID and sequential contact ID, e.g., Confirm	med case CA102034567 has contacts CA102034567 -01 and
CA102034567 -02. <sup>b</sup> For NNDSS reporters, use GenV2 or NETSS patient id			
Interviewer information			
Name of interviewer: Last			
Affiliation/Organization:	Telephor	ne Email	
Basic information			
What is the current status of this person?  PUI, testing pending* PUI, tested negative* Presumptive case (positive local test), confirmatory testing pending† Presumptive case (positive local test), confirmatory tested negative† Laboratory-confirmed case† *Testing performed by state, local, or CDC lab. †At this time, all confirmatory testing occurs at CDC  Report date of PUI to CDC (MM/DD/YYYY): /  Report date of case to CDC (MM/DD/YYYY):/  County of residence: State of residence: State of residence:  Race (check all that apply):  Asian Black Native Hawaiian/G White Unknown Other, specify: Date of birth (MM/DD/YYYY):/		Date of first positive specimen collection (MM/DD/YYYY):	Was the patient hospitalized?  Yes No Unknown  If yes, admission date 1  /_/(MM/DD/YYYY)  If yes, discharge date 1  /(MM/DD/YYYY)  Was the patient admitted to an intensive care unit (ICU)?  Yes No Unknown  Did the patient receive mechanical ventilation (MV)/intubation?  Yes No Unknown  If yes, total days with MV (days)  ————  Did the patient receive ECMO?  Yes No Unknown  Did the patient die as a result of this illness?  Yes No Unknown  Date of death (MM/DD/YYYY):
Age units(yr/mo/day):  Symptoms present during course of illness: Symptomatic Asymptomatic Unknown  If symptomatic, onset date (MM/DD/YYYY):  Unknown	/	of symptom resolution (MM/DD/YYYY):  Unknown symptom status  ed, unknown date	
Travel to Hubei lab-co Travel to mainland China Any ho Travel to other non-US country lab-co specify: P	cility (as a patient, working of the following exponential contact with anoundirmed COVID-19 case althorage COVID-19 case atient Visitor exposure	osures (check all that apply): ther	No

☐ Contact tracing of case patient ☐ Routine surveillance ☐ EpiX notification of travelers; if checked, DGMQID\_

☐ Unknown ☐ Other, specify:\_



0000000	
CDC 2019-nCoV ID:	

Form Approved: OMB: 0920-1011 Exp. 4/23/2020

# Human Infection with 2019 Novel Coronavirus Person Under Investigation (PUI) and Case Report Form

Symptoms, clinical course, past medical history and social history
Collected from (check all that apply): 

Patient interview

Medical record review

During this illness, did the patient experience any of the following symptoms?		Symptom Present?				
Fever >100.4F (38C) <sup>c</sup>		☐Yes [	No	Unk		
Subjective fever (felt feverish)		Yes [	No	Unk		
Chills		Yes	No	Unk		
Muscle aches (myalgia)		Yes	No	Unk		
Runny nose (rhinorrhea)			No	Unk		
Sore throat		Yes	No	Unk		
Cough (new onset or worsening of chronic cough)		∐Yes [	No	Unk		
Shortness of breath (dyspnea)		Yes	No	Unk		
Nausea or vomiting		Yes [	No	Unk		
Headache		∐Yes [	No	Unk		
Abdominal pain		☐ Yes	No	Unk		
Diarrhea (≥3 loose/looser than normal stools/24hr period)		Yes	No	Unk		
Other, specify:						
Pre-existing medical conditions?				Yes No	Unknown	
Chronic Lung Disease (asthma/emphysema/COPD)	]No ☐Unknowr	ı				
Diabetes Mellitus Yes	No Unknowr	1				
Cardiovascular disease Yes	No Unknowr	1				
Chronic Renal disease	No ☐Unknowr					
Chronic Liver disease	No Unknowr					
Immunocompromised Condition	No Unknowr					
· · · · · · · · · · · · · · · · · · ·			/14	YES, specify)		
Neurologic/neurodevelopmental/intellectual Yes L disability	No Unknowr	'	(11	res, specify)		
	No Unknowr	1	(11	YES, specify)		
If female, currently pregnant	]No ☐Unknowr	1				
Current smoker Yes	No ∏Unknowr	1				
Former smoker Yes	No Unknowr	1				
Respiratory Diagnostic Testing	Specimens for CC					
Test Pos Neg Pend. Not		Specimen	Date		e Lab Sent to	CDC La
done	Type	ID	Collecte	d Tested Re	sult CDC	Result
Influenza rapid Ag 🗆 A 🗆 B 🔛 📙 📗	NP Swab					
Influenza PCR 🗆 A 🗆 B	OP Swab				<u> </u>	
RSV	Sputum					
H. metapneumovirus	Other,					
Parainfluenza (1-4)	Specify:					
Adenovirus						
Rhinovirus/enterovirus						
Coronavirus (OC43, 229E,						
HKU1, NL63)						
M. pneumoniae						
	1					
C. pneumoniae						